<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231201011145&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20231201011145&amp;utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Fri, 01 Dec 2023 06:11:47 +0000</lastbuilddate>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>MINT trial signals potential benefit of liberal transfusion strategy in MI with anaemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 30. doi: 10.1038/s41569-023-00969-w. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38036672</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00969-w>10.1038/s41569-023-00969-w</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036672</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>MINT trial signals potential benefit of liberal transfusion strategy in MI with anaemia</dc:title>
<dc:identifier>pmid:38036672</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00969-w</dc:identifier>
</item>
<item>
<title>PCI for stable angina</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036671/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 30. doi: 10.1038/s41569-023-00967-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036671/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38036671</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00967-y>10.1038/s41569-023-00967-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036671</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>PCI for stable angina</dc:title>
<dc:identifier>pmid:38036671</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00967-y</dc:identifier>
</item>
<item>
<title>Non-invasive ultrasound therapy for calcified aortic valve stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036670/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 30. doi: 10.1038/s41569-023-00968-x. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036670/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38036670</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00968-x>10.1038/s41569-023-00968-x</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036670</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Non-invasive ultrasound therapy for calcified aortic valve stenosis</dc:title>
<dc:identifier>pmid:38036670</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00968-x</dc:identifier>
</item>
<item>
<title>SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036669/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 30. doi: 10.1038/s41569-023-00970-3. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036669/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38036669</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00970-3>10.1038/s41569-023-00970-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036669</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes</dc:title>
<dc:identifier>pmid:38036669</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00970-3</dc:identifier>
</item>
<item>
<title>A very rare and unusual complication after a percutaneous patent foramen ovale closure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036461/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 30:ehad800. doi: 10.1093/eurheartj/ehad800. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036461/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38036461</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad800>10.1093/eurheartj/ehad800</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036461</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Claudiu Ungureanu</dc:creator>
<dc:creator>Giuseppe Colletti</dc:creator>
<dc:creator>Jacques Auslender</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A very rare and unusual complication after a percutaneous patent foramen ovale closure</dc:title>
<dc:identifier>pmid:38036461</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad800</dc:identifier>
</item>
<item>
<title>Quality and transparency of clinical evidence for high-risk cardiovascular medical devices: a long way to go</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036418/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 30:ehad786. doi: 10.1093/eurheartj/ehad786. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036418/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38036418</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad786>10.1093/eurheartj/ehad786</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036418</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Piotr Szymański</dc:creator>
<dc:creator>Rita Redberg</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Quality and transparency of clinical evidence for high-risk cardiovascular medical devices: a long way to go</dc:title>
<dc:identifier>pmid:38036418</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad786</dc:identifier>
</item>
<item>
<title>Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036416/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Macrophage P2Y6R regulates phospholipase Cβ/store-operated calcium entry/calreticulin signalling pathway to increase scavenger receptor A protein level, thereby improving foam cell formation and atherosclerosis, indicating that the P2Y6R may be a potential therapeutic target for intervention of atherosclerotic diseases using P2Y6R antagonists including thiamine pyrophosphate.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 30:ehad796. doi: 10.1093/eurheartj/ehad796. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Macrophage-derived foam cells play a causal role during the pathogenesis of atherosclerosis. P2Y6 receptor (P2Y6R) highly expressed has been considered as a disease-causing factor in atherogenesis, but the detailed mechanism remains unknown. This study aims to explore P2Y6R in regulation of macrophage foaming, atherogenesis, and its downstream pathways. Furthermore, the present study sought to find a potent P2Y6R antagonist and investigate the feasibility of P2Y6R-targeting therapy for atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The P2Y6R expression was examined in human atherosclerotic plaques and mouse artery. Atherosclerosis animal models were established in whole-body P2Y6R or macrophage-specific P2Y6R knockout mice to evaluate the role of P2Y6R. RNA sequencing, DNA pull-down experiments, and proteomic approaches were performed to investigate the downstream mechanisms. High-throughput Glide docking pipeline from repurposing drug library was performed to find potent P2Y6R antagonists.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The P2Y6R deficiency alleviated atherogenesis characterized by decreasing plaque formation and lipid deposition of the aorta. Mechanically, deletion of macrophage P2Y6R significantly inhibited uptake of oxidized low-density lipoprotein through decreasing scavenger receptor A expression mediated by phospholipase Cβ/store-operated calcium entry pathways. More importantly, P2Y6R deficiency reduced the binding of scavenger receptor A to CALR, accompanied by dissociation of calreticulin and STIM1. Interestingly, thiamine pyrophosphate was found as a potent P2Y6R antagonist with excellent P2Y6R antagonistic activity and binding affinity, of which the pharmacodynamic effect and mechanism on atherosclerosis were verified.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Macrophage P2Y6R regulates phospholipase Cβ/store-operated calcium entry/calreticulin signalling pathway to increase scavenger receptor A protein level, thereby improving foam cell formation and atherosclerosis, indicating that the P2Y6R may be a potential therapeutic target for intervention of atherosclerotic diseases using P2Y6R antagonists including thiamine pyrophosphate.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036416/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38036416</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad796>10.1093/eurheartj/ehad796</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036416</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Yehong Li</dc:creator>
<dc:creator>Mengze Zhou</dc:creator>
<dc:creator>Huanqiu Li</dc:creator>
<dc:creator>Chen Dai</dc:creator>
<dc:creator>Li Yin</dc:creator>
<dc:creator>Chunxiao Liu</dc:creator>
<dc:creator>Yuxin Li</dc:creator>
<dc:creator>Enming Zhang</dc:creator>
<dc:creator>Xinli Dong</dc:creator>
<dc:creator>Hui Ji</dc:creator>
<dc:creator>Qinghua Hu</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways</dc:title>
<dc:identifier>pmid:38036416</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad796</dc:identifier>
</item>
<item>
<title>Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38036414/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Real-world data from the ELEVATE registry demonstrate an overall survival rate for primary implants of 63.3%. In the PIC, reductions in adverse events for patients in the extended follow-up and improved QoL and functional capacity were observed at 5 years in this patient population with advanced heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 30:ehad658. doi: 10.1093/eurheartj/ehad658. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: HeartMate 3 (HM3) is a fully magnetically levitated continuous flow left ventricular assist device, which received CE marking in 2015. The ELEVATE Registry was initiated to collect real-world outcomes in patients treated with HM3 post-CE Mark approval.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 540 subjects implanted at 26 centres between March 2015 and February 2017 were included in this registry. Of these, 463 received the device as a primary implant (primary implant cohort, PIC), 19 as a pump exchange (pump exchange cohort), and in 58 patients, only anonymized survival data were collected (anonymized cohort, AC). Patients in the PIC contributed to the baseline demographics, survival, adverse events, quality of life (QoL) (EuroQoL-5 Dimensions-5 Levels visual analogue scale), and functional capacity (6 min walk distance) assessments, while patients in the AC contributed only to survival.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Primary implant cohort patients had a mean age of 56 years and were predominantly male (89%) with 48% ischaemic aetiology. The majority of subjects was designated bridge to transplant (66%) and had INTERMACS Profiles 1-3 (70%). At baseline, the subjects had poor functional capacity (104 ± 140 m) and impaired QoL (35 ± 19 points). The overall survival rate of the PIC was 63.3% and survival free of stroke was 58.1% at 5 years. Significant improvements in functional capacity and QoL were observed and maintained for 5 years (301 ± 131 m and 64 ± 20 points, respectively).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Real-world data from the ELEVATE registry demonstrate an overall survival rate for primary implants of 63.3%. In the PIC, reductions in adverse events for patients in the extended follow-up and improved QoL and functional capacity were observed at 5 years in this patient population with advanced heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38036414/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38036414</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad658>10.1093/eurheartj/ehad658</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38036414</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Jan D Schmitto</dc:creator>
<dc:creator>Steven Shaw</dc:creator>
<dc:creator>Jens Garbade</dc:creator>
<dc:creator>Finn Gustafsson</dc:creator>
<dc:creator>Michiel Morshuis</dc:creator>
<dc:creator>Daniel Zimpfer</dc:creator>
<dc:creator>Jacob Lavee</dc:creator>
<dc:creator>Yuriy Pya</dc:creator>
<dc:creator>Michael Berchtold-Herz</dc:creator>
<dc:creator>AiJia Wang</dc:creator>
<dc:creator>Carlo Gazzola</dc:creator>
<dc:creator>Evgenij Potapov</dc:creator>
<dc:creator>Diyar Saeed</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry</dc:title>
<dc:identifier>pmid:38036414</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad658</dc:identifier>
</item>
<item>
<title>2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38033089/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>AIM: The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 30. doi: 10.1161/CIR.0000000000001193. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">AIM: The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STRUCTURE: Atrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally. Recommendations from the "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" and the "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation" have been updated with new evidence to guide clinicians. In addition, new recommendations addressing atrial fibrillation and thromboembolic risk assessment, anticoagulation, left atrial appendage occlusion, atrial fibrillation catheter or surgical ablation, and risk factor modification and atrial fibrillation prevention have been developed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38033089/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38033089</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001193>10.1161/CIR.0000000000001193</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38033089</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>José A Joglar</dc:creator>
<dc:creator>Mina K Chung</dc:creator>
<dc:creator>Anastasia L Armbruster</dc:creator>
<dc:creator>Emelia J Benjamin</dc:creator>
<dc:creator>Janice Y Chyou</dc:creator>
<dc:creator>Edmond M Cronin</dc:creator>
<dc:creator>Anita Deswal</dc:creator>
<dc:creator>Lee L Eckhardt</dc:creator>
<dc:creator>Zachary D Goldberger</dc:creator>
<dc:creator>Rakesh Gopinathannair</dc:creator>
<dc:creator>Bulent Gorenek</dc:creator>
<dc:creator>Paul L Hess</dc:creator>
<dc:creator>Mark Hlatky</dc:creator>
<dc:creator>Gail Hogan</dc:creator>
<dc:creator>Chinwe Ibeh</dc:creator>
<dc:creator>Julia H Indik</dc:creator>
<dc:creator>Kazuhiko Kido</dc:creator>
<dc:creator>Fred Kusumoto</dc:creator>
<dc:creator>Mark S Link</dc:creator>
<dc:creator>Kathleen T Linta</dc:creator>
<dc:creator>Gregory M Marcus</dc:creator>
<dc:creator>Patrick M McCarthy</dc:creator>
<dc:creator>Nimesh Patel</dc:creator>
<dc:creator>Kristen K Patton</dc:creator>
<dc:creator>Marco V Perez</dc:creator>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:creator>Andrea M Russo</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Megan M Streur</dc:creator>
<dc:creator>Kevin L Thomas</dc:creator>
<dc:creator>Sabrina Times</dc:creator>
<dc:creator>James E Tisdale</dc:creator>
<dc:creator>Anne Marie Valente</dc:creator>
<dc:creator>David R Van Wagoner</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</dc:title>
<dc:identifier>pmid:38033089</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001193</dc:identifier>
</item>
<item>
<title>Perspective on ACC/AHA/ACCP/HRS Guidelines for the Management of Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38033049/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 30. doi: 10.1161/CIRCULATIONAHA.123.066919. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38033049/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38033049</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066919>10.1161/CIRCULATIONAHA.123.066919</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38033049</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Angela Khidhir</dc:creator>
<dc:creator>Anne B Curtis</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Perspective on ACC/AHA/ACCP/HRS Guidelines for the Management of Atrial Fibrillation</dc:title>
<dc:identifier>pmid:38033049</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066919</dc:identifier>
</item>
<item>
<title>Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38031887/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Independent of brachial BP, a biochemical phenotype of subclinical primary aldosteronism is negatively associated with cardiovascular health, including greater arterial stiffness, adverse cardiac remodeling, and incident hypertension.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 30. doi: 10.1161/CIRCULATIONAHA.123.066389. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Primary aldosteronism, characterized by overt renin-independent aldosterone production, is a common but underrecognized form of hypertension and cardiovascular disease. Growing evidence suggests that milder and subclinical forms of primary aldosteronism are highly prevalent, yet their contribution to cardiovascular disease is not well characterized.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This prospective study included 1284 participants between the ages of 40 and 69 years from the randomly sampled population-based CARTaGENE cohort (Québec, Canada). Regression models were used to analyze associations of aldosterone, renin, and the aldosterone-to-renin ratio with the following measures of cardiovascular health: arterial stiffness, assessed by central blood pressure (BP) and pulse wave velocity; adverse cardiac remodeling, captured by cardiac magnetic resonance imaging, including indexed maximum left atrial volume, left ventricular mass index, left ventricular remodeling index, and left ventricular hypertrophy; and incident hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The mean (SD) age of participants was 54 (8) years and 51% were men. The mean (SD) systolic and diastolic BP were 123 (15) and 72 (10) mm Hg, respectively. At baseline, 736 participants (57%) had normal BP and 548 (43%) had hypertension. Higher aldosterone-to-renin ratio, indicative of renin-independent aldosteronism (ie, subclinical primary aldosteronism), was associated with increased arterial stiffness, including increased central BP and pulse wave velocity, along with adverse cardiac remodeling, including increased indexed maximum left atrial volume, left ventricular mass index, and left ventricular remodeling index (all <i>P</i>&lt;0.05). Higher aldosterone-to-renin ratio was also associated with higher odds of left ventricular hypertrophy (odds ratio, 1.32 [95% CI, 1.002-1.73]) and higher odds of developing incident hypertension (odds ratio, 1.29 [95% CI, 1.03-1.62]). All the associations were consistent when assessing participants with normal BP in isolation and were independent of brachial BP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Independent of brachial BP, a biochemical phenotype of subclinical primary aldosteronism is negatively associated with cardiovascular health, including greater arterial stiffness, adverse cardiac remodeling, and incident hypertension.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38031887/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38031887</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066389>10.1161/CIRCULATIONAHA.123.066389</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38031887</guid>
<pubDate>Thu, 30 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Gregory L Hundemer</dc:creator>
<dc:creator>Mohsen Agharazii</dc:creator>
<dc:creator>François Madore</dc:creator>
<dc:creator>Anand Vaidya</dc:creator>
<dc:creator>Jenifer M Brown</dc:creator>
<dc:creator>Alexander A Leung</dc:creator>
<dc:creator>Gregory A Kline</dc:creator>
<dc:creator>Eric Larose</dc:creator>
<dc:creator>Marie-Eve Piché</dc:creator>
<dc:creator>Andrew M Crean</dc:creator>
<dc:creator>Julie L V Shaw</dc:creator>
<dc:creator>Tim Ramsay</dc:creator>
<dc:creator>Bernhard Hametner</dc:creator>
<dc:creator>Siegfried Wassertheurer</dc:creator>
<dc:creator>Manish M Sood</dc:creator>
<dc:creator>Swapnil Hiremath</dc:creator>
<dc:creator>Marcel Ruzicka</dc:creator>
<dc:creator>Rémi Goupil</dc:creator>
<dc:date>2023-11-30</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study</dc:title>
<dc:identifier>pmid:38031887</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066389</dc:identifier>
</item>
<item>
<title>Reply: Causal Pathway of Alcohol Intake: Stress-Related Neuronal Activity and Cardiovascular Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38030356/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 5;82(23):e227-e228. doi: 10.1016/j.jacc.2023.09.825.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38030356/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38030356</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.825>10.1016/j.jacc.2023.09.825</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38030356</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Kenechukwu Mezue</dc:creator>
<dc:creator>Shady Abohashem</dc:creator>
<dc:creator>Michael T Osborne</dc:creator>
<dc:creator>Ahmed Tawakol</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Causal Pathway of Alcohol Intake: Stress-Related Neuronal Activity and Cardiovascular Risk</dc:title>
<dc:identifier>pmid:38030356</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.825</dc:identifier>
</item>
<item>
<title>Causal Pathway of Alcohol Intake: Stress-Related Neuronal Activity and Cardiovascular Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38030355/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 5;82(23):e225. doi: 10.1016/j.jacc.2023.06.055.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38030355/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38030355</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.055>10.1016/j.jacc.2023.06.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38030355</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Gopisankar Mohanannair Geethadevi</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Causal Pathway of Alcohol Intake: Stress-Related Neuronal Activity and Cardiovascular Risk</dc:title>
<dc:identifier>pmid:38030355</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.055</dc:identifier>
</item>
<item>
<title>Reporting Extended Follow-Up in Cardiovascular Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38030354/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 5;82(23):2246-2250. doi: 10.1016/j.jacc.2023.09.827.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38030354/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38030354</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.827>10.1016/j.jacc.2023.09.827</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38030354</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Mario Gaudino</dc:creator>
<dc:creator>Stuart Pocock</dc:creator>
<dc:creator>Frank Rockhold</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reporting Extended Follow-Up in Cardiovascular Clinical Trials</dc:title>
<dc:identifier>pmid:38030354</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.827</dc:identifier>
</item>
<item>
<title>Neuroimaging and Neurodevelopmental Outcomes Among Individuals With Complex Congenital Heart Disease: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38030353/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>Although neuroimaging advances have deepened our understanding of brain health in individuals with congenital heart disease (CHD), it is less clear how neuroimaging findings relate to neurodevelopmental and mental health outcomes across the lifespan. We systematically synthesized and critically evaluated evidence on associations between neuroimaging and neurodevelopmental, neurocognitive, psychiatric, or behavioral outcomes among individuals with transposition of great arteries or...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 5;82(23):2225-2245. doi: 10.1016/j.jacc.2023.09.824.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Although neuroimaging advances have deepened our understanding of brain health in individuals with congenital heart disease (CHD), it is less clear how neuroimaging findings relate to neurodevelopmental and mental health outcomes across the lifespan. We systematically synthesized and critically evaluated evidence on associations between neuroimaging and neurodevelopmental, neurocognitive, psychiatric, or behavioral outcomes among individuals with transposition of great arteries or single-ventricle CHD (Protocol CRD42021229617). Six databases were searched and 45 papers from 25 unique studies were identified. Structural brain injury was generally linked to poorer neurodevelopment in infancy. Brain volumes and microstructural and functional brain changes appear linked to neurocognitive outcomes, including deficits in attention, learning, memory, and executive function in children and adolescents. Fetal neuroimaging studies were limited. Four papers investigated psychiatric outcomes; none found associations with neuroimaging. Multicenter, longitudinal studies incorporating functional neuroimaging and mental health outcomes are much-needed to inform early neuroprotective and therapeutic strategies in CHD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38030353/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38030353</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.824>10.1016/j.jacc.2023.09.824</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38030353</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Katelyn Phillips</dc:creator>
<dc:creator>Bridget Callaghan</dc:creator>
<dc:creator>Vidya Rajagopalan</dc:creator>
<dc:creator>Farah Akram</dc:creator>
<dc:creator>Jane W Newburger</dc:creator>
<dc:creator>Nadine A Kasparian</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Neuroimaging and Neurodevelopmental Outcomes Among Individuals With Complex Congenital Heart Disease: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38030353</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.824</dc:identifier>
</item>
<item>
<title>A Responsibility to Perpetually Seek Improved Risk Stratification Models: Achieving Data Nirvana</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38030352/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 5;82(23):2222-2224. doi: 10.1016/j.jacc.2023.10.004.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38030352/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38030352</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.004>10.1016/j.jacc.2023.10.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38030352</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>S Adil Husain</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Responsibility to Perpetually Seek Improved Risk Stratification Models: Achieving Data Nirvana</dc:title>
<dc:identifier>pmid:38030352</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.004</dc:identifier>
</item>
<item>
<title>Adjusting for Congenital Heart Surgery Risk Using Administrative Data</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38030351/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: We created and validated a risk-adjustment model for CHS that accounts for patient and procedural characteristics associated with in-hospital mortality available in administrative data, including the newly developed RACHS-2. Our risk model will be critical for use in health services research and quality improvement initiatives.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 5;82(23):2212-2221. doi: 10.1016/j.jacc.2023.09.826.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Congenital heart surgery (CHS) encompasses a heterogeneous population of patients and surgeries. Risk standardization models that adjust for patient and procedural characteristics can allow for collective study of these disparate patients and procedures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We sought to develop a risk-adjustment model for CHS using the newly developed Risk Stratification for Congenital Heart Surgery for ICD-10 Administrative Data (RACHS-2) methodology.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Within the Kids' Inpatient Database 2019, we identified all CHSs that could be assigned a RACHS-2 score. Hierarchical logistic regression (clustered on hospital) was used to identify patient and procedural characteristics associated with in-hospital mortality. Model validation was performed using data from 24 State Inpatient Databases during 2017.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 5,902,538 total weighted hospital discharges in the Kids' Inpatient Database 2019, 22,310 pediatric cardiac surgeries were identified and assigned a RACHS-2 score. In-hospital mortality occurred in 543 (2.4%) of cases. Using only RACHS-2, the mortality mode had a C-statistic of 0.81 that improved to 0.83 with the addition of age. A final multivariable model inclusive of RACHS-2, age, payer, and presence of a complex chronic condition outside of congenital heart disease further improved model discrimination to 0.87 (P &lt; 0.001). Discrimination in the validation cohort was also very good with a C-statistic of 0.83.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We created and validated a risk-adjustment model for CHS that accounts for patient and procedural characteristics associated with in-hospital mortality available in administrative data, including the newly developed RACHS-2. Our risk model will be critical for use in health services research and quality improvement initiatives.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38030351/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38030351</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.826>10.1016/j.jacc.2023.09.826</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38030351</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Natalie Jayaram</dc:creator>
<dc:creator>Philip Allen</dc:creator>
<dc:creator>Matthew Hall</dc:creator>
<dc:creator>Tara Karamlou</dc:creator>
<dc:creator>Joyce Woo</dc:creator>
<dc:creator>Sarah Crook</dc:creator>
<dc:creator>Brett R Anderson</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Adjusting for Congenital Heart Surgery Risk Using Administrative Data</dc:title>
<dc:identifier>pmid:38030351</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.826</dc:identifier>
</item>
<item>
<title>Systemic Atrioventricular Valve Regurgitation in Corrected Transposition of the Great Arteries: Where Are We?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38030350/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 5;82(23):2209-2211. doi: 10.1016/j.jacc.2023.10.022.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38030350/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38030350</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.022>10.1016/j.jacc.2023.10.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38030350</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Sitaram M Emani</dc:creator>
<dc:creator>Pedro J Del Nido</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Systemic Atrioventricular Valve Regurgitation in Corrected Transposition of the Great Arteries: Where Are We?</dc:title>
<dc:identifier>pmid:38030350</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.022</dc:identifier>
</item>
<item>
<title>Systemic Atrioventricular Valve Surgery in Patients With Congenitally Corrected Transposition of the Great Vessels</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38030349/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: SAVV surgery remains a valuable option for the treatment of patients with ccTGA, with low early mortality and satisfactory long-term outcomes, particularly in those with SVEF ≥40%. Timely referral and accurate patient selection are the keys to better long-term outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 5;82(23):2197-2208. doi: 10.1016/j.jacc.2023.09.822.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Limited data exist regarding the long-term outcomes of systemic atrioventricular valve (SAVV) intervention (morphologic tricuspid valve) in congenitally corrected transposition (ccTGA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to evaluate the mid- and long-term outcomes of SAVV surgery in ccTGA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed a retrospective review of 108 ccTGA patients undergoing SAVV surgery from 1979 to 2022. The primary outcome was a composite endpoint of mortality, cardiac transplantation, or ventricular assist device implantation. The secondary outcome was long-term systemic right ventricular ejection fraction (SVEF). Cox proportional hazard and linear regression models were used to analyze survival and late SVEF data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The median age at surgery was 39.5 years (Q1-Q3: 28.8-51.0 years), and the median preoperative SVEF was 39% (Q1-Q3: 33.2%-45.0%). Intrinsic valve abnormality was the most common mechanism of SAVV regurgitation (76.9%). There was 1 early postoperative mortality (0.9%). Postoperative complete heart block occurred in 20 patients (18.5%). The actuarial 5-, 10-, and 20-year freedom from death or transplantation was 92.4%, 79.1%, and 62.9%. The 10- and 20-year freedom from valve reoperation was 100% and 93% for mechanical prosthesis compared with 56.6% and 15.7% for bioprosthesis (P &lt; 0.0001). Predictors of postoperative mortality were age at operation (P = 0.01) and preoperative SVEF (P = 0.04). Preoperative SVEF (P &lt; 0.001), complex ccTGA (P = 0.02), severe SAVV regurgitation (P = 0.04), and preoperative creatinine (P = 0.003) were predictors of late postoperative SVEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SAVV surgery remains a valuable option for the treatment of patients with ccTGA, with low early mortality and satisfactory long-term outcomes, particularly in those with SVEF ≥40%. Timely referral and accurate patient selection are the keys to better long-term outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38030349/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38030349</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.822>10.1016/j.jacc.2023.09.822</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38030349</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ahmed A Abdelrehim</dc:creator>
<dc:creator>Elizabeth H Stephens</dc:creator>
<dc:creator>William R Miranda</dc:creator>
<dc:creator>Austin L Todd</dc:creator>
<dc:creator>Heidi M Connolly</dc:creator>
<dc:creator>Alexander C Egbe</dc:creator>
<dc:creator>Luke J Burchill</dc:creator>
<dc:creator>Elena A Ashikhmina</dc:creator>
<dc:creator>Joseph A Dearani</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Systemic Atrioventricular Valve Surgery in Patients With Congenitally Corrected Transposition of the Great Vessels</dc:title>
<dc:identifier>pmid:38030349</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.822</dc:identifier>
</item>
<item>
<title>Age-Related Changes of Pulmonary Artery Systolic Pressure: Prevention Is Key</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38030348/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 5;82(23):2193-2196. doi: 10.1016/j.jacc.2023.10.006.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38030348/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38030348</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.10.006>10.1016/j.jacc.2023.10.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38030348</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Bernhard Haring</dc:creator>
<dc:creator>Philipp Markwirth</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Age-Related Changes of Pulmonary Artery Systolic Pressure: Prevention Is Key</dc:title>
<dc:identifier>pmid:38030348</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.10.006</dc:identifier>
</item>
<item>
<title>Changes in Pulmonary Artery Pressure Late in Life: The Atherosclerosis Risk in Communities (ARIC) Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38030347/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231201011145&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Pulmonary pressure increased over 6.5 years in late life, was associated with concomitant increases in LV filling pressure, and predicted the development of dyspnea. Interventions targeting LV diastolic function may be effective at mitigating age-related increases in PASP.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Dec 5;82(23):2179-2192. doi: 10.1016/j.jacc.2023.09.821.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Although the prognostic implications of higher pulmonary artery systolic pressure (PASP) are well established, few data exist regarding longitudinal change in pulmonary pressure in late life.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to quantify changes in PASP over 6 years and determine the relative contributions of cardiac and pulmonary dysfunction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Among 1,420 participants in the ARIC (Atherosclerosis Risk in Communities) study with echocardiographic measures of PASP at both the fifth (2011-2013) and seventh (2018-2019) visits, longitudinal changes in PASP over about 6.5 years were quantified. Multivariable regression was used to determine the extent to which cardiac and pulmonary dysfunction were associated with changes in PASP and to define the relationship of changes in PASP with dyspnea development.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The mean age was 75 ± 5 years at visit 5 and 81 ± 5 years at visit 7, 24% of subjects were Black adults, and 68% were women. Over the 6.5 years, PASP increased by 5 ± 8 mm Hg, from 28 ± 5 to 33 ± 8 mm Hg. PASP increased more in older participants. Predictors of greater increases in PASP included worse left ventricular (LV) systolic and diastolic function, pulmonary function, and renal function. Increases in PASP were associated with concomitant increases in measures of LV filling pressure, including E/e' ratio and left atrial volume index. Each 5 mm Hg increase was associated with 16% higher odds of developing dyspnea (OR: 1.16; 95% CI: 1.07-1.27; P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Pulmonary pressure increased over 6.5 years in late life, was associated with concomitant increases in LV filling pressure, and predicted the development of dyspnea. Interventions targeting LV diastolic function may be effective at mitigating age-related increases in PASP.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38030347/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231201011145&v=2.17.9.post6+86293ac">38030347</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.821>10.1016/j.jacc.2023.09.821</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38030347</guid>
<pubDate>Wed, 29 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Rani Zierath</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Victoria Arthur</dc:creator>
<dc:creator>Yimin Yang</dc:creator>
<dc:creator>Hicham Skali</dc:creator>
<dc:creator>Kunihiro Matsushita</dc:creator>
<dc:creator>Dalane Kitzman</dc:creator>
<dc:creator>Suma Konety</dc:creator>
<dc:creator>Thomas Mosley</dc:creator>
<dc:creator>Amil M Shah</dc:creator>
<dc:date>2023-11-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Changes in Pulmonary Artery Pressure Late in Life: The Atherosclerosis Risk in Communities (ARIC) Study</dc:title>
<dc:identifier>pmid:38030347</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.821</dc:identifier>
</item>





























</channel>
</rss>